Predictive Dose-Based Estimation of Systemic Exposure Multiples in Mouse and Monkey Relative to Human for Antisense Oligonucleotides With 2′-O-(2-Methoxyethyl) Modifications

被引:35
|
作者
Yu, Rosie Z. [1 ]
Grundy, John S. [1 ]
Henry, Scott P. [1 ]
Kim, Tae-Won [1 ]
Norris, Daniel A. [1 ]
Burkey, Jennifer [1 ]
Wang, Yanfeng [1 ]
Vick, Andrew [2 ]
Geary, Richard S. [1 ]
机构
[1] Isis Pharmaceut Inc, Preclin & Clin Dev, Carlsbad, CA 92010 USA
[2] WIL Res Labs, Analyt Serv, Ashland, OH USA
来源
关键词
APOLIPOPROTEIN-B; PHASE-I; PHARMACOKINETICS; CHOLESTEROL; INHIBITOR;
D O I
10.1038/mtna.2014.69
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Evaluation of species differences and systemic exposure multiples (or ratios) in toxicological animal species versus human is an ongoing exercise during the course of drug development. The systemic exposure ratios are best estimated by directly comparing area under the plasma concentration-time curves (AUCs), and sometimes by comparing the dose administered, with the dose being adjusted either by body surface area (BSA) or body weight (BW). In this study, the association between AUC ratio and the administered dose ratio from animals to human were studied using a retrospective data-driven approach. The dataset included nine antisense oligonucleotides (ASOs) with 2'-O-(2-methoxyethyl) modifications, evaluated in two animal species (mouse and monkey) following single and repeated parenteral administrations. We found that plasma AUCs were similar between ASOs within the same species, and are predictable to human exposure using a single animal species, either mouse or monkey. Between monkey and human, the plasma exposure ratio can be predicted directly based on BW-adjusted dose ratios, whereas between mouse and human, the exposure ratio would be nearly fivefold lower in mouse compared to human based on BW-adjusted dose values. Thus, multiplying a factor of 5 for the mouse BW-adjusted dose would likely provide a reasonable AUC exposure estimate in human at steady-state.
引用
收藏
页数:8
相关论文
共 6 条
  • [1] Absolute bioavailability of 2′-O-(2-methoxyethyl)-modified antisense oligonucleotides following intraduodenal instillation in rats
    Geary, RS
    Khatsenko, O
    Bunker, K
    Crooke, R
    Moore, M
    Burckin, T
    Truong, L
    Sasmor, H
    Levin, AA
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2001, 296 (03): : 898 - 904
  • [2] Lack of Interactions Between an Antisense Oligonucleotide with 2′-O-(2-Methoxyethyl) Modifications and Major Drug Transporters
    Yu, Rosie Z.
    Warren, Mark S.
    Watanabe, Tanya
    Nichols, Brandon
    Jahic, Mirza
    Huang, Jane
    Burkey, Jennifer
    Geary, Richard S.
    Henry, Scott P.
    Wang, Yanfeng
    NUCLEIC ACID THERAPEUTICS, 2016, 26 (02) : 111 - 117
  • [3] Antisense oligonucleotides containing 3′-O-methyl, 3′-O-(2-fluoroethyl) and 3′-O-(2-methoxyethyl) D-altritol nucleoside analogs
    Prakash, Thazha P.
    Siwkowski, Andrew
    Berdeja, Andres
    Gaus, Hans J.
    Pandey, Sanjay
    Bhat, Balkrishen
    Swayze, Eric E.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2011, 241
  • [4] In Vitro Metabolic Stabilities and Metabolism of 2′-O-(Methoxyethyl) Partially Modified Phosphorothioate Antisense Oligonucleotides in Preincubated Rat or Human Whole Liver Homogenates
    Baek, Min-Son
    Yu, Rosie Z.
    Gaus, Hans
    Grundy, John S.
    Geary, Richard S.
    OLIGONUCLEOTIDES, 2010, 20 (06) : 309 - 316
  • [5] Local and systemic tolerability of a 2′O-methoxyethyl antisense oligonucleotide targeting interleukin-4 receptor-α delivery by inhalation in mouse and monkey
    Fey, Robert A.
    Templin, Michael V.
    McDonald, Jacob D.
    Yu, Rosie Z.
    Hutt, Julie A.
    Gigliotti, Andrew P.
    Henry, Scott P.
    Reed, Matthew D.
    INHALATION TOXICOLOGY, 2014, 26 (08) : 452 - 463
  • [6] Lack of QT Prolongation for 2′-O-Methoxyethyl-Modified Antisense Oligonucleotides Based on Retrospective Exposure/Response Analysis of Ten Phase 1 Dose-Escalation Placebo-Controlled Studies in Healthy Subjects
    Yu, Rosie Z.
    Gunawan, Rudy
    Geary, Richard S.
    Hughes, Steven G.
    Henry, Scott P.
    Wang, Yanfeng
    NUCLEIC ACID THERAPEUTICS, 2017, 27 (05) : 285 - 294